Clinical Benefit of Entrectinib for Patients With Metastatic Pancreatic Cancer

Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown University Lombardi Comprehensive Cancer Center, discusses the results of a study investigating entrectinib in patients with metastatic pancreatic cancer who harbor <em>NTRK</em> and <em>ROS1</em> fusions.

Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown University Lombardi Comprehensive Cancer Center, discusses the results of a study investigating entrectinib in patients with metastatic pancreatic cancer who harborNTRKandROS1fusions.

Entrectinib was given to 2 patients withNTRKfusions and 1 patient with aROS1fusion and was well tolerated. All of the patients maintained a high level of quality of life while on the study. Two of the patients experienced a response and long-term stabilization of their disease.

Though this was a small subgroup of patients, the drug looked very promising, and there was a better outcome than what is typically seen in patients who receive chemotherapy, Pishvaian says.